Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.52 |
| ▸ | LPAR2 | Q9HBW0 | 7/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 6/20 | 0.52 |
| ▸ | CES2 | O00748 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17878608 | 0.82 | LPAR3 (0.47) | LPAR3LPAR2LPAR1CES2CYP3A4 | |
| SCHEMBL17860871 | 0.80 | CYP3A4 (0.48) | LPAR3LPAR2LPAR1CES2CYP3A4 | |
| SCHEMBL27959316 | 0.73 | LPAR3 (0.62) | LPAR3LPAR2LPAR1 | |
| SCHEMBL17860873 | 0.72 | LMNA (0.33) | LPAR3LPAR2LPAR1CES2CYP3A4 | |
| SCHEMBL16996799 | 0.72 | LPAR3 (0.61) | LPAR3LPAR2LPAR1CES2CYP3A4 | |
| SCHEMBL9396740 | 0.71 | LPAR3 (0.55) | LPAR3LPAR2LPAR1CYP3A4 | |
| SCHEMBL2459739 | 0.71 | LPAR3 (0.65) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL1582974 | 0.71 | LPAR3 (0.95) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL497151 | 0.71 | LPAR3 (0.71) | LPAR3LPAR2LPAR1CYP3A4LPAR5 | |
| SCHEMBL56778 | 0.71 | LPAR3 (0.95) | LPAR3LPAR2LPAR1CYP3A4LPAR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233889-B1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | SHANGHAI MICURX PHARMACEUTICAL CO LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| WO-2016100578-A2 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | VIP, AQP1, PEF1 | LPAR3 2783/4885LPAR2 4266/4885LPAR1 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.